Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 3/20 | 0.47 |
| ▸ | CTSS | P25774 | 3/20 | 0.46 |
| ▸ | CTSK | P43235 | 3/20 | 0.46 |
| ▸ | PPARA | Q07869 | 6/20 | 0.45 |
| ▸ | PPARG | P37231 | 5/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | KDM4A | O75164 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648928 | 0.89 | ACE (0.53) | SCN9AACECTSSCTSKPPARA | |
| SCHEMBL649126 | 0.89 | ACE (0.53) | SCN9AACECTSSCTSKPPARA | |
| SCHEMBL391142 | 0.89 | ACE (0.53) | SCN9AACECTSSCTSKPPARA | |
| SCHEMBL30829401 | 0.89 | ACE (0.53) | SCN9AACECTSSCTSKPPARA | |
| SCHEMBL30829406 | 0.89 | ACE (0.53) | SCN9AACECTSSCTSKPPARA | |
| SCHEMBL6367780 | 0.86 | BCL2 (0.54) | SCN9AACECTSSCTSKPPARA | |
| SCHEMBL7281390 | 0.83 | ALDH1A1 (0.52) | ACEPPARAPPARGALDH1A1HTT | |
| SCHEMBL29467176 | 0.83 | ALDH1A1 (0.52) | ACEPPARAPPARGALDH1A1HTT | |
| SCHEMBL15565625 | 0.83 | ALDH1A1 (0.52) | ACEPPARAPPARGALDH1A1HTT | |
| SCHEMBL8903146 | 0.83 | ALDH1A1 (0.52) | ACEPPARAPPARGALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054398-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-1996202-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007104933-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054398-A1 | CHEMICAL COMPOUNDS | NOTCH1, HES1, NOTCH2 | SCN9A 1777/4885ACE 1364/4885CTSS 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.